Drug Type Bispecific antibody |
Synonyms IMM 2521, IMM-2521, IMM2521 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), SIRPα inhibitors(Signal-regulatory protein alpha inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 10 Dec 2021 |